Japan’s Astellas Pharma has a US patent on Flomax, which is used for the treatment of benign prostatic hyperplasia, until October 27, 2009.
Astellas, and Boehringer Ingelheim of Germany, together market Flomax in the US. The court decision to prevent Ranbaxy from producing a generic version of the drug was made in New Jersey, US.